

Galaxy Surfactants Ltd.

August 13, 2025

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex,

Bandra (East) Mumbai – 400 051

Scrip Symbol: GALAXYSURF

BSE Limited,

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400001

Scrip Code: 540935

Sub: Investor presentation on the Unaudited Financial Results for the quarter ended June 30, 2025.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation on the Unaudited Financial Results for the quarter ended June 30, 2025.

The information is also hosted in announcement section on the website of the Company at www.galaxysurfactants.com.

We request you to take the same on record.

Yours faithfully,

For Galaxy Surfactants Limited

Niranjan Ketkar

Company Secretary encl: as above

Communication Address:

Rupa Solitaire, Ground Floor, Unit no. 8, 12A and 14 Millennium Business Park, Mahape, Navi Mumbai, 400 710

Ph: +91-22-33063700

Regd. Office: C-49/2, TTC Industrial Area, Pawne, Navi Mumbai-400 703, India CIN: L39877MH1986PLC039877

Ph: +91-22-27616666

Fax: +91-22-27615883/ 27615886 e-mail: galaxy@galaxysurfactants.com Website: www.galaxysurfactants.com



Galaxy Surfactants Limited



Result Presentation August'25



Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Galaxy Surfactants Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.





Company at a Glance





215+ Product Grades

Performance Surfactants: 47+ Speciality Care Products: 168+



Extensive R&D Capabilities

100+ Members
R&D Centre
Pilot Plant

Product Application Centre



7 Strategically Located
Facilities with Inhouse
Project Execution Capabilities

5 in India 1 in Egypt 1 in US



Serving 1,500+ Clients



Presence across 80+ countries



2,000+ Employees across all our Facilities



As on 30th June 2025

Quarterly Performance Highlights





Q1FY26: Key Developments



01

In Q1FY26, volumes grew by 5% YoY, with sequential growth nearing double digits across Performance and Specialty care segments

02

EBIDTA grew by 4.3% YoY in line with volume growth

EBIDTA /MT remains at the same level on YoY basis to ₹ 20,009/MT Q1FY26 vs ₹ 20,197/MT Q1FY25

03

ROW region experienced High doubledigit volume driven by masstige categories

04

AMET volumes remain flat on YoY

05

India's volumes grew in low single digits YoY and double-digit QoQ

06

Fatty alcohol prices remained buoyant, with supply-side challenges persisting due to tight raw material availability and regional congestion



Management Commentary





Mr. K. Natarajan Managing Director

"Q1FY26 Volume grew at 5% YoY and nearly double-digit sequential across both performance and specialty care segments, reflecting a sign of improvement across all regions.

India's domestic performance reflects a market in transition and evolution, with flat YoY and double-digit QoQ volume growth. Strategic product adjustments in response to multinational shifts, coupled with favorable macro factors such as a good monsoon, rate cuts, and rural stimulus, support a cautiously optimistic outlook.

In AMET, while Egypt and Turkey faced headwinds, resilience in Gulf and Sub-Saharan markets helped maintain momentum. Our supply chains adapted swiftly despite geopolitical tensions, ensuring continuity and responsiveness.

ROW region led growth with a strong 16% YoY increase, driven by LATAM and APAC, while Europe delivered a richer product mix aligned with our Vision 2030. Supply-side challenges persisted with tight raw material availability and regional congestion, but price pass-through mechanisms and inventory vigilance helped mitigate impact.

As we reaffirm our long-term strategy, we remain focused on innovation, agility, and sustainability—confident in our ability to navigate current complexities and deliver enduring value to all stakeholders."






Q1FY26: Consolidated Financial Highlights



₹ In Crores







Q1FY26: Segment Performance Highlights



Segment-wise Revenue & Volume Performance

Performance Surfactants Revenue

₹ 840.5 cr

Specialty Care Revenue

₹ 448.6 cr

Total Revenue

₹ 1,289.2 cr

Overall Volume growth remains Mid Single digit on YoY

Region-wise Volume Performance



INDIA

Flat vs YoY



AMET

Flat vs YoY




ROW

High Double digit growth vs YoY



Q1FY26: Revenue Performance










Managing Volatility in Raw Material Prices and Currency...



Fatty Alcohol Prices (USD / MT)

INR / USD Prices





... through Robust Risk Management Practices



Source: Market Prices – ICIS – LOR Source: RBI



Consolidated Profit & Loss Statement



Particulars (₹ In Crores)	Q1FY26	Q1FY25	Y-o-Y	Q4FY25	Q-o-Q	FY25
Net Revenue from Operations	1,277.9	974.1	31.2%	1,144.9	11.6%	4,223.7
Other Income	11.2	5.4		7.8		25.8
Total Revenue	1,289.2	979.5	31.6%	1,152.7	11.8%	4,249.5
Cost of Material Consumed	942.8	647.0		808.4		2,885.6
Employee's Benefits Expense	83.5	76.9		75.8		302.5
Other Expenses	127.8	126.1		133.8		551.3
EBITDA	135.1	129.5	4.3%	134.7	0.3%	510.0
EBITDA Margin	10.5%	13.2%		11.7%		12.0%
Depreciation	29.3	26.6		28.3		110.3
ЕВІТ	105.8	102.9	2.8%	106.3	-0.5%	399.7
Finance cost	6.6	4.0		6.2		19.3
РВТ	99.2	98.9	0.3%	100.1	-0.9%	380.5
Tax expense	19.7	19.2		24.3		75.5
PAT	79.5	79.7	-0.3%	75.9	4.8%	304.9
PAT Margin	6.2%	8.1%		6.6%		7.2%
Other Comprehensive Income	1.9	0.2		-7.1		20.2
Total Comprehensive Income	81.4	79.9	1.8%	68.8	18.3%	325.1
EPS	22.42*	22.48*		21.40*		86.00

Fatty Alcohol prices in this quarter increased to an average price of \$ 2,723/MT vs Q4 when it stood at \$ 2,494/MT. The same was \$ 1,548/MT in Q1FY25





Standalone Profit & Loss Statement



Particulars (₹. In Crores)	Q1FY26	Q1FY25	Y-o-Y	Q4FY25	Q-o-Q	FY25
Net Revenue from Operations	874.1	677.5	29.0%	814.3	7.3%	3,001.3
Other Income	6.5	1.0		6.7		26.5
Total Revenue	880.6	678.5	29.8%	820.9	7.3%	3,027.7
Cost of Material Consumed	672.8	479.4		608.2		2,170.2
Employee's Benefits Expense	46.2	44.0		40.6		171.1
Other Expenses	79.4	88.0		90.5		377.9
EBITDA	82.2	67.0	22.7%	81.7	0.6%	308.5
EBITDA Margin	9.3%	9.9%		10.0%		10.2%
Depreciation	18.0	16.2		17.1		67.2
EBIT	64.2	50.9	26.1%	64.7	-0.7%	241.4
Finance cost	5.7	3.4		5.3		16.6
РВТ	58.5	47.4	23.2%	59.3	-1.4%	224.8
Tax expense	16.4	11.9		15.3		51.0
PAT	42.0	35.5	18.4%	44.0	-4.5%	173.8
PAT Margin	4.8%	5.2%		5.4%		5.7%
Other Comprehensive Income	-0.1	0.2		-3.4		-2.8
Total Comprehensive Income	41.9	35.7	17.3%	40.7	3.0%	171.0
EPS	11.86*	10.02*		12.42*		49.03



Vision 2030







Vision 2030: The Contours



2x **Volumes**

2.5x **EBITDA** 22%+ **ROCE**

Defend and Grow in India and AMET

Winning in Americas

Winning in Specialities in EU



Focus Industry

- **HOME CARE**
- **PERSONAL CARE**
- **BEAUTY & WELLNESS**



Performance Surfactants

DEFEND & GROW

- ✓ AMET ✓ INDIA
- **CHALLENGE & PENETRATE**
- **✓** AMERICAS ✓ ROW



Specialty Care Products

3D

ITT

✓ Innovation

- Development
- ✓ Digitalisation
- Distribution



- ✓ Technology







Thank You

Company



CIN No: L39877MH1986PLC039877

Mr. Ruchir Soni

Email: Ruchir.Soni@galaxysurfactants.com

www.galaxysurfactants.com

Investor Relations Advisors:

SGA Strategic Growth Advisors

CIN - U74140MH2010PTC204285

Mr. Mandar Chavan / Mr. Rahul Agarwal

mandar.chavan@sgapl.net /

rahul.agarwal@sgapl.net

+91 96993 82195 / +91 98214 38864

www.sgapl.net